Illumina stock is trading -16.74% below its average target price of $163.36 after marking a 3.9% during today's afternoon session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $120.0 to $252.0 per share.
The stock has an average amount of shares sold short at 4.7%, and a short ratio of 3.2. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 103.8% of Illumina's shares being owned by this investor type.
Institutions Invested in Illumina
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 12% | 18,546,274 | $2,522,478,624 |
| 2024-09-30 | Vanguard Group Inc | 10% | 15,914,200 | $2,164,490,254 |
| 2024-09-30 | State Street Corporation | 4% | 5,607,824 | $762,720,111 |
| 2024-09-30 | Loomis Sayles & Company, LP | 3% | 4,342,740 | $590,656,043 |
| 2024-09-30 | Baillie Gifford and Company | 2% | 3,622,813 | $492,738,776 |
| 2024-09-30 | Capital World Investors | 2% | 3,544,069 | $482,028,805 |
| 2024-09-30 | Bank Of New York Mellon Corporation | 2% | 3,374,439 | $458,957,429 |
| 2024-09-30 | WCM Investment Management, LLC | 2% | 3,262,182 | $443,689,355 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 2,727,827 | $371,011,735 |
| 2024-09-30 | Guardcap Asset Management Ltd. | 2% | 2,724,818 | $370,602,481 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Illumina.
